SCHEMBL2652793

SCHEMBL2652793

CS(=O)(=O)c1ccc(C2(C(=O)Nc3nccs3)CC2C2CCCCC2)cc1OC(F)(F)F

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 9/20 0.68
KCNH2 Q12809 2/20 0.44
EGFR P00533 3/20 0.38
KDR P35968 3/20 0.38
FGFR1 P11362 2/20 0.38
POLB P06746 1/20 0.38
SCN3A Q9NY46 2/20 0.37
SCN1A P35498 1/20 0.37
SCN5A Q14524 1/20 0.37
SCN9A Q15858 1/20 0.37
SCN2A Q99250 1/20 0.37
SCN8A Q9UQD0 1/20 0.37
SCN10A Q9Y5Y9 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 1/20 0.37
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13757063 1.00 GCK (0.68) GCKKCNH2EGFRKDRFGFR1
SCHEMBL1582471 0.88 GCK (0.71) GCKKCNH2POLBMEN1KMT2A
SCHEMBL12720791 0.88 GCK (0.71) GCKKCNH2POLBMEN1KMT2A
SCHEMBL13757080 0.87 GCK (0.50) GCKPOLBSCN9AMEN1KMT2A
SCHEMBL13757059 0.87 GCK (0.74) GCKKCNH2POLBSCN1ASCN5A
SCHEMBL1581651 0.87 GCK (0.74) GCKKCNH2POLBSCN1ASCN5A
SCHEMBL2666311 0.82 GCK (0.64) GCKKCNH2POLBMEN1KMT2A
SCHEMBL1581979 0.82 GCK (0.64) GCKKCNH2POLBMEN1KMT2A
SCHEMBL362258 0.81 GCK (1.00) GCKMEN1KMT2AALDH1A1USP2
SCHEMBL1581869 0.81 GCK (1.00) GCKMEN1KMT2AALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US claimed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 GCK 1/4885KCNH2 710/4885EGFR 2673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.